LEVONORGESTREL Drug Patent Profile

Which patents cover Levonorgestrel, and what generic alternatives are available?

Levonorgestrel is a drug marketed by Wyeth Pharms Inc, Alvogen, Annora Pharma, Fdn Consumer, Glenmark Pharms Ltd, L Perrigo Co, Laboratoire Hra, Lotus Pharm Co Ltd, Lupin Ltd, Naari Pte, Novel Labs Inc, Perrigo R And D, Watson Labs, Xiromed, Barr, Amneal Pharms, Dr Reddys Labs Sa, and Hetero Labs. and is included in forty-seven NDAs.

The generic ingredient in LEVONORGESTREL is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

Summary for LEVONORGESTREL

US Patents:	0
Applicants:	18
NDAs:	47
Finished Product Suppliers / Packagers:	15
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	281
Patent Applications:	4,265
Drug Prices:	Drug price information for LEVONORGESTREL
What excipients (inactive ingredients) are in LEVONORGESTREL?	LEVONORGESTREL excipients list
DailyMed Link:	LEVONORGESTREL at DailyMed

See drug prices for LEVONORGESTREL

See drug sales revenues for LEVONORGESTREL

Recent Clinical Trials for LEVONORGESTREL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	PHASE2
Premier Research	PHASE2
HIV Prevention Trials Network	PHASE2

See all LEVONORGESTREL clinical trials

Pharmacology for LEVONORGESTREL

Drug Class	Progestin Progestin-containing Intrauterine Device Progestin-containing Intrauterine System
Physiological Effect	Inhibit Ovum Fertilization

Medical Subject Heading (MeSH) Categories for LEVONORGESTREL

Contraceptive Agents, Female

Contraceptives, Oral, Synthetic

Anatomical Therapeutic Chemical (ATC) Classes for LEVONORGESTREL

G03AC	Progestogens
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

G03AD	Emergency contraceptives
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for LEVONORGESTREL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys Labs Sa	LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL	ethinyl estradiol; levonorgestrel	TABLET;ORAL	200407-001	Oct 25, 2011		DISCN	No	No
Hetero Labs	LEVONORGESTREL AND ETHINYL ESTRADIOL	ethinyl estradiol; levonorgestrel	TABLET;ORAL-28	212298-001	Feb 13, 2023	AB1	RX	No	No
Xiromed	LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL	ethinyl estradiol; levonorgestrel	TABLET;ORAL	200493-001	Jun 17, 2015	AB	RX	No	No
Amneal Pharms	LEVONORGESTREL AND ETHINYL ESTRADIOL	ethinyl estradiol; levonorgestrel	TABLET;ORAL-28	201095-001	Dec 8, 2014		DISCN	No	No
Lupin Ltd	LEVONORGESTREL AND ETHINYL ESTRADIOL	ethinyl estradiol; levonorgestrel	TABLET;ORAL-28	091425-001	Jan 18, 2013	AB1	RX	No	No

Market Dynamics and Financial Trajectory for Levonorgestrel

Last updated: February 19, 2026

Levonorgestrel is a widely used progestin hormone for contraception and emergency pregnancy prevention. Its market has expanded driven by regulatory, demographic, and technological factors, with sustained revenue growth projected over the next decade.

Market Overview

Levonorgestrel is integral to oral contraceptives, intrauterine devices, implants, and emergency contraceptive pills. The global market was valued at approximately USD 2.8 billion in 2022. It is expected to reach USD 4.5 billion by 2030, growing at an estimated CAGR of 6.1% (2023-2030). The compound annual growth rate (CAGR) reflects increasing adoption and expanding indications, buoyed by regulatory approvals and consumer demand.

Key Market Drivers

• Increasing contraceptive use: Rising awareness about family planning drives demand. The World Health Organization reports 63% of women aged 15-49 use some form of contraception globally.
• Emergency contraception acceptance: The recent approval of over-the-counter sales in multiple regions facilitates broader access.
• Product innovation: Development of low-dose formulations and novel delivery systems (e.g., implants) enhances adherence and expands market opportunities.
• Regulatory approvals: New formulations and expanded indications in emerging markets like Africa and Southeast Asia increase product penetration.

Market Segmentation

Segment	Key Insights	Revenue (2022)	Projected CAGR (2023-2030)
Oral contraceptives	Largest segment, driven by prescription and OTC sales.	USD 1.4B	5.8%
Intrauterine devices (IUDs)	Growing with increased acceptance due to safety profile.	USD 0.9B	6.5%
Emergency contraceptive pills	Rapid growth due to OTC accessibility and awareness.	USD 0.4B	8.0%
Implants and injections	Emerging segment, in early adoption phase.	USD 0.1B	7.2%

Competitive Landscape

Major pharmaceutical players include:

• Bayer AG: Markets the Levonorgestrel-containing intrauterine device Mirena and emergency contraceptive Plan B One-Step.
• HRA Pharma: Focuses on OTC emergency contraceptive brands like NorLevo.
• MediGene AG: Offers generic levonorgestrel formulations for oral and implantable systems.

Patent expiration timelines influence the generic entry, impacting pricing and margins. The primary patents for oral formulations in the U.S. expired between 2014-2017, increasing generic competition and compressing profit margins in developed markets.

Regulatory and Patent Environment

• The U.S. Food and Drug Administration (FDA) approved Plan B One-Step for OTC sale in 2013.
• European Medicines Agency (EMA) granted marketing authorization for various levonorgestrel formulations since 1998.
• Patent protections generally expired in key markets, enabling generics from 2014 onwards.
• Emerging markets lack patent protections or have shorter durations, resulting in lower prices and higher volume sales.

Financial Trajectory

Projected revenue growth is driven by:

• Market Expansion: Broadened access in emerging regions.
• Product Diversification: Introduction of new delivery systems.
• Regulatory Trends: Favorable approvals for OTC availability.

Year	Estimated Revenue (USD billion)	Market Share of Top Players	Avg. Price per Unit (USD)
2022	2.8	Bayer (40%), HRA Pharma (15%)	10
2025	3.8	Bayer (35%), generics (20%)	8
2030	4.5	Generics (50%), Innovators (20%)	7

Margins for generic manufacturers are compressed due to price erosion, but sales volume compensates for lower per-unit revenue. Innovative formulations and branded products retain higher margins but face patent cliffs.

Conclusion

Levonorgestrel’s market is characterized by steady growth, driven by demographic trends, regulatory changes, and product innovation. Volume-driven growth in generics and expanding OTC sales support revenue increase. Price competition and patent expirations pose risks of margin compression for branded products but open opportunities for generic manufacturers and biosimilar entry.

Key Takeaways

• Revenue is projected to grow from USD 2.8 billion in 2022 to USD 4.5 billion in 2030.
• CAGR estimates range from 5.8% in oral contraceptives to 8.0% in emergency contraceptives.
• Patent expirations have catalyzed generic entry, influencing pricing strategies.
• Emerging markets offer substantial growth potential due to increasing contraceptive use and regulatory shifts.
• Product innovation and OTC availability are critical to capturing additional market share.

FAQs

1. How do patent expirations impact levonorgestrel market revenue?
Patent expirations enable generic manufacturers to enter markets, increasing competition and driving down prices. Revenue for brand-name products declines unless offset by new formulations or indications.

2. What regulatory trends could influence future sales?
Expanding OTC availability, especially for emergency contraceptives, increases access, thereby boosting sales. Regulatory approvals in emerging markets further open revenue streams.

3. Which regions show the highest growth potential?
Africa, Southeast Asia, and Latin America demonstrate high growth potential due to rising contraceptive adoption, expanding healthcare infrastructure, and regulatory liberalization.

4. How does product innovation affect market dynamics?
Developing new delivery systems (e.g., implants) and formulations (lower doses, combination products) can extend product lifecycle and differentiate offerings, impacting market share.

5. What competitive strategies are prevalent?
Key strategies include patent filing, expanding OTC access, developing biosimilars, and offering cost-effective generics to gain market share in mature and emerging segments.

References

[1] Grand View Research. (2023). Levonorgestrel Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2022). Global Contraceptive Market Trends.
[3] EMA. (2022). Summary of Product Characteristics for Levonorgestrel.
[4] FDA. (2013). Approval Letter for Plan B One-Step.